Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126096271 | 12609627 | 1 | I | 20110625 | 20130112 | 20160801 | 20160801 | EXP | US-ROCHE-1179658 | ROCHE | 60.00 | YR | F | Y | 72.30000 | KG | 20160801 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126096271 | 12609627 | 1 | PS | Vismodegib | VISMODEGIB | 1 | Oral | TOTAL DOSE ADMINISTERED ON MOST RECENT COURSE: 3150MG. LAST ADMINISTERED 27/MAR/2011 | U | 203388 | 3150 | MG | CAPSULE | QD | |||||
| 126096271 | 12609627 | 2 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | ||||||||||
| 126096271 | 12609627 | 3 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 4 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 5 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 6 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3300 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 7 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 2100 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 8 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 2700 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 9 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 1650 | MG | CAPSULE | |||||||
| 126096271 | 12609627 | 10 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | TOTAL DOSE ADMINISTERED ON MOST RECENT COURSE: 558MG. LAST ADMINISTERED 09/MAR/2011 | U | 0 | 100 | MG/M**2 | |||||||
| 126096271 | 12609627 | 11 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | TOTAL DOSE ADMINISTERED ON MOST RECENT COURSE: 140MG. LAST ADMINISTERED 07/MAR/2011 | U | 0 | 75 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126096271 | 12609627 | 1 | Small cell lung cancer |
| 126096271 | 12609627 | 10 | Small cell lung cancer |
| 126096271 | 12609627 | 11 | Small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126096271 | 12609627 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126096271 | 12609627 | Ear pain | |
| 126096271 | 12609627 | Embolism | |
| 126096271 | 12609627 | Fatigue | |
| 126096271 | 12609627 | Insomnia | |
| 126096271 | 12609627 | Neutrophil count decreased | |
| 126096271 | 12609627 | Non-cardiac chest pain | |
| 126096271 | 12609627 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126096271 | 12609627 | 1 | 20110214 | 0 | ||
| 126096271 | 12609627 | 2 | 20110611 | 20110726 | 0 | |
| 126096271 | 12609627 | 3 | 20110307 | 0 | ||
| 126096271 | 12609627 | 4 | 20110328 | 0 | ||
| 126096271 | 12609627 | 5 | 20110421 | 0 | ||
| 126096271 | 12609627 | 6 | 20110512 | 0 | ||
| 126096271 | 12609627 | 7 | 20110603 | 0 | ||
| 126096271 | 12609627 | 8 | 20110625 | 0 | ||
| 126096271 | 12609627 | 9 | 20110716 | 0 | ||
| 126096271 | 12609627 | 10 | 20110214 | 20110726 | 0 | |
| 126096271 | 12609627 | 11 | 20110214 | 20110726 | 0 |